Compare AXTI & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTI | OCGN |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 387.3M |
| IPO Year | 1998 | 2014 |
| Metric | AXTI | OCGN |
|---|---|---|
| Price | $38.13 | $1.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $24.50 | $7.00 |
| AVG Volume (30 Days) | ★ 7.2M | 5.2M |
| Earning Date | 05-15-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.71 | 31.58 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,361,000.00 | N/A |
| Revenue This Year | $44.70 | N/A |
| Revenue Next Year | $42.23 | $4,139.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.09 | N/A |
| 52 Week Low | $1.13 | $0.52 |
| 52 Week High | $47.00 | $2.00 |
| Indicator | AXTI | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 50.57 |
| Support Level | $2.56 | $1.44 |
| Resistance Level | $47.00 | $1.88 |
| Average True Range (ATR) | 5.01 | 0.16 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 64.07 | 43.22 |
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").